-
-
-
-
-
-
-
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
-
-
-
-
-
-
-
RedHill Biopharma (RDHL) Reports FDA Approval of Talicia for Treatment of H. pylori in Adults
-
-
-
-
-
-
-
RedHill Biopharma (RDHL) Announces New European and Japanese Patents for Talicia
-
-
-
-
-
-
-
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
-
-
-
-
-
-
-
RedHill Biopharma (RDHL) Reports Completion of Enrollment for Confirmatory Phase III Study with TALICIA for H. pylori Infection
-
-
-
-
-
-
-
RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
-
-
-
-
-
-
-
RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study
-
2,758 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All